Josh Wolfe is a co-founder and Managing Partner of Lux Capital focusing on the firms' venture investments in physical & life sciences. He has led Lux's direct investments in Nanosys, Molecular Imprints, Cambrios, Crystal IS, Silicon Clocks and Magen. Mr. Wolfe sits on the Board of Crystal IS, Silicon Clocks, Lux Research and Angstrom Publishing.
Before forming Lux Capital, he worked in Salomon Smith Barney's Investment Banking group, Merrill Lynch's Financial Futures Options/Government Strategy Group, and Prudential Securities Municipal Finance department. He also serves on Merrill Lynch's TechBrains Advisory Board. Mr. Wolfe was a Westinghouse semi-finalist at fifteen and published cutting edge HIV/AIDS and immunopathology research. He has been published in Nature Biotechnology, Cell Vision and The Journal of Leukocyte Biology, leading medical/immunology journals.
Mr. Wolfe has a column at Forbes magazine, is the author of "The Nanotech Report" and Editor of "Forbes/Wolfe Emerging Tech Report." He founded the NanoBusiness Alliance and joined President Bush during the signing of the 21st Century Nanotech R&D Act. Steve Forbes called Lux a "powerhouse of nanotech brainpower" and Mr. Wolfe "America's Leading Authority on Nanotechnology."
He was named by Crain's magazine as one of their "40 under 40" and has appeared in Business Week, The New York Times, Forbes, The Wall Street Journal, Wired, CBS News, The New York Post and has been a regular guest on CNBC's Kudlow & Cramer, Bullseye and Closing Bell. He is a founding member of junior boards for The East Harlem School at Exodus House, the Hospital for Special Surgery, Coney Island Prep and the Cancer Research Institute. He graduated with distinction from Cornell University with a B.S. in Economics and Finance.